Background
swapnil hiremath
Metformin- Should I Stay or Should I Go

This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

Metformin- Should I Stay or Should I Go
Background
Brian Rifkin
KDIGO 2025 ADPKD Guidelines Review

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD.  These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.


KDIGO 2025 ADPKD Guidelines Review
Background
Cristina Adriana Popa
REGENCY: A B-Cell Super Destroyer in Lupus

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨

REGENCY: A B-Cell Super Destroyer in Lupus
Background
Cristina Adriana Popa
Hunting Primary Hyperaldosteronism: are MRAs a ...

This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions

Hunting Primary Hyperaldosteronism: are MRAs a blindfold in adrenal vein sampling?
Background
Brian Rifkin
Undercover Aldosterone

This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?

Undercover Aldosterone

hiperaldosteronismo primario

¿Los ARMs dificultan la identificación del HAP unilateral en el MVA?

¿Usar o no los antagonistas del receptor de mineralocorticoides para el diagnóstico de HAP en el muestreo venoso adrenal? 🤔
💡 ¿Mito o realidad? ¡Vamos a descubrirlo juntos!

🗣️ Únete al chat y comparte tu opinión! #NephJC

La Aldosterona en la sombra

El hiperaldosteronismo primario (HAP) no es solo una entidad de hipertensión resistente; este estudio revela un continuo fisiopatológico que inicia en personas normotensas.

A través de pruebas dinámicas, ¿podría el HAP ser la base oculta de una proporción significativa de la hipertensión? ¿Cómo cambia nuestro enfoque en el diagnóstico y tratamiento?

👀 Veamos el resumen visual creado por Brian Rifkin 🎨✨ y 💬 únete a la conversación en #NephJC por Bluesky.